NCT05954091View on ClinicalTrials.gov

OH2 Administered by Intratumoral Injection

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

January 1, 2028

Conditions
Solid Tumor
Interventions
DRUG

OH2 Injection

OH2 injection will be given intratumorally, and Q2W.

Sponsors
All Listed Sponsors
lead

Binhui Biopharmaceutical Co., Ltd.

INDUSTRY